300049 Stock Overview
Inner Mongolia Furui Medical Science Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Inner Mongolia Furui Medical Science Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥37.82 |
| 52 Week High | CN¥57.50 |
| 52 Week Low | CN¥28.73 |
| Beta | -0.25 |
| 11 Month Change | -9.06% |
| 3 Month Change | -10.38% |
| 1 Year Change | -10.87% |
| 33 Year Change | 196.63% |
| 5 Year Change | 413.86% |
| Change since IPO | 65.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300049 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.4% | 3.7% | 2.3% |
| 1Y | -10.9% | -5.7% | 5.6% |
Return vs Industry: 300049 underperformed the CN Pharmaceuticals industry which returned -7% over the past year.
Return vs Market: 300049 underperformed the CN Market which returned 4.2% over the past year.
Price Volatility
| 300049 volatility | |
|---|---|
| 300049 Average Weekly Movement | 11.2% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300049's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300049's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 703 | Guanyi Wang | www.fu-rui.com |
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. It operates in two segments, pharmaceutical production and sales; and diagnostic equipment R&D, production and sales.
Inner Mongolia Furui Medical Science Co., Ltd. Fundamentals Summary
| 300049 fundamental statistics | |
|---|---|
| Market cap | CN¥10.06b |
| Earnings (TTM) | CN¥130.40m |
| Revenue (TTM) | CN¥1.33b |
77.2x
P/E Ratio7.6x
P/S RatioIs 300049 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300049 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.33b |
| Cost of Revenue | CN¥335.03m |
| Gross Profit | CN¥991.56m |
| Other Expenses | CN¥861.16m |
| Earnings | CN¥130.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.49 |
| Gross Margin | 74.74% |
| Net Profit Margin | 9.83% |
| Debt/Equity Ratio | 0% |
How did 300049 perform over the long term?
See historical performance and comparison